Paving the Road to the Clinic: Translational Oncology & Immuno-oncology Tumor Models

Register to view on-demand recording

On_Demand_Recording_In_Vitro_and_In_Vivo_Translational_Models-01-01

First Name*
Last Name*
Company Name*
Job Title*
Email*
From time to time, we would like to contact you about our products and services, events, and company updates. If you consent to receiving these communications please check the box below.*
- I agree to receive email communications from BioDuro
You may unsubscribe from these communications at any time. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list. For more information on our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Understanding Patient Response to Treatment Before Entering the Clinic

Recent advancements in immunotherapy are shifting the way that cancer is treated. The development of immuno-oncology therapies is creating the need for programs tailored to subsets of patients who are most likely to respond positively to treatment. Predictive preclinical models and translational strategies are needed to understand which patient populations will benefit from treatment and identify biomarkers of response.

This presentation covers:

Importance of the tumor microenvironment
In vivo models and translational results
PDX Case Study: Building Confidence in NSCLC Clinical Population
Preclinical profiling of patient populations

Presenter

Tommy Broudy, PhD

Executive VP, Translational Sciences & Strategy, BioDuro

Presentation: